The Condensed List contains products that have at least one patent with compound, composition or "new polymorph, salt or hydrate" claims.
Patents whose numbers are in italics have been extended under 35 USC 156. All expiration dates include applicable Sec. 156 and pediatric (PED) extensions.
Products tagged as [GENERIC] have had a generic equivalent approved for at least one strength of the product.
MIVACRON; MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE) MIVACURIUM CHLORIDE
NDA Applicant: ABBOTT NDA No.: 020098 Prod. No.: 001 RX (EQ 2MG BASE/ML) NDA No.: 020098 Prod. No.: 002 DISC (EQ 0.5MG BASE/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4761418 [Extended 173 days (0.5 years)] Novel compounds Claim Types: Compound; Composition; Method of use | Jan 22, 2006 |
MAXAQUIN (TABLET) LOMEFLOXACIN HYDROCHLORIDE
Drug Classes: ANTIBACTERIALS, MISCELLANEOUS
NDA Applicant: PHARMACIA NDA No.: 020013 Prod. No.: 001 RX (EQ 400MG BASE)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4528287 [Extended 522 days* (1.4 years)] 6-Fluoro-1, 4-dihydro-4-oxo-7-substituted piperazinylquinoline-3-carboxylic acids and the method for preparing the same Claim Types: Compound; Composition; Method of use | Feb 21, 2006 | U-36: Methods of treating bacterial illnesses |
FLOMAX (CAPSULE) TAMSULOSIN HYDROCHLORIDE
Drug Classes: ANTIHYPERTENSIVES
NDA Applicant: BOEHRINGER INGELHEIM NDA No.: 020579 Prod. No.: 001 RX (0.4MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4772475 Controlled-release multiple units pharmaceutical formulation Claim Types: Product-by-process | Feb 27, 2006 | |
| Pat. No. 4868216 Sulfamoyl-substituted phenethylamine derivatives and process of producing them Claim Types: Method of use | Sep 19, 2006 | U-181: Producing alpha adrenergic antagonistic action in a host |
| Pat. No. 4703063 [Extended 5 years] Sulfamoyl substituted phenethylamine derivatives and process of producing them Claim Types: Compound; Composition | Oct 27, 2009 |
PRAVACHOL (TABLET) PRAVASTATIN SODIUM [GENERIC AB]
Drug Classes: HYPERLIPIDEMIA; CARDIOVASCULAR-RENAL
NDA Applicant: BRISTOL MYERS SQUIBB NDA No.: 019898 Prod. No.: 002 RX (10MG); 003 RX (20MG); 004 RX (40MG); 008 RX (80MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4346227 [Extended 1598 days (4.4 years)] ML-236B Derivatives and their preparation Claim Types: Compound | Apr 20, 2006 *PED | |
| Pat. No. 5030447 Pharmaceutical compositions having good stability Claim Types: Formulation | Jan 9, 2009 *PED | |
| Pat. No. 5180589 Pravastatin pharmaceuatical compositions having good stability Claim Types: Formulation; Process | Jan 9, 2009 *PED | |
| Pat. No. 5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor Claim Types: Method of use | Oct 22, 2014 *PED | U-335: Use of pravastatin sodium for secondary prevention of coronary events in men and women who have had a myocardial infarction and have normal cholesterol levels |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: I - New Indication | Apr 29,2006 PED | I-370: Treatment of heterozygous familial hypercholesterolemia in children, ages 8-13 years, with recommended dose of 20mg once daily and in adolescents, ages 14-18 with a recommended dose of 40mg once daily |
PRAVIGARD PAC (COPACKAGED) (TABLET, TABLET) ASPIRIN; PRAVASTATIN SODIUM
Drug Classes: CARDIOVASCULAR-RENAL; HYPERLIPIDEMIA
NDA Applicant: BRISTOL MYERS SQUIBB NDA No.: 021387 Prod. No.: 001 RX (81MG,N/A;N/A,20MG); 002 RX (81MG,N/A;N/A,40MG); 003 RX (81MG,N/A;N/A,80MG); 004 RX (325MG,N/A;N/A,20MG); 005 RX (325MG,N/A;N/A,40MG); 006 RX (325MG,N/A;N/A,80MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4346227 [Extended 1598 days (4.4 years)] ML-236B Derivatives and their preparation Claim Types: Compound | Apr 20, 2006 *PED | |
| Pat. No. 5030447 Pharmaceutical compositions having good stability Claim Types: Formulation | Jan 9, 2009 *PED | |
| Pat. No. 5180589 Pravastatin pharmaceuatical compositions having good stability Claim Types: Formulation; Process | Jan 9, 2009 *PED | |
| Pat. No. 5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor Claim Types: Method of use | Oct 22, 2014 *PED | U-335: Use of pravastatin sodium for secondary prevention of coronary events in men and women who have had a myocardial infarction and have normal cholesterol levels |
HEPSERA (TABLET) ADEFOVIR DIPIVOXIL
NDA Applicant: GILEAD NDA No.: 021449 Prod. No.: 001 RX (10MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4724233 Therapeutical application of phosphonylmethoxyalkyl adenines Claim Types: Method of use | Apr 21, 2006 | U-470: Therapy in chronic hepatitis B virus infection |
| Pat. No. 4808716 9-(phosponylmethoxyalkyl) adenines, the method of preparation and utilization thereof Claim Types: Compound | Apr 25, 2006 | |
| Pat. No. 5663159 DS* DP* Prodrugs of phosphonates Claim Types: Compound; Method of use | Sep 2, 2014 | U-470: Therapy in chronic hepatitis B virus infection |
| Pat. No. 6451340 DS* DP* Nucleotide analog compositions Claim Types: New polymorph, salt or hydrate; Method of use; Process; Product-by-process; Formulation | Jul 23, 2018 | U-470: Therapy in chronic hepatitis B virus infection |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: NCE - New chemical entity | SEP 20,2007 |
PREMPRO (PREMARIN;CYCRIN) (TABLET) ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
NDA Applicant: WYETH PHARMS INC NDA No.: 020303 Prod. No.: 001 DISC (0.625MG,0.625MG;2.5MG,2.5MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. RE36247 Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens Claim Types: Method of use; Formulation | May 2, 2006 | U-284: Menopausal and postmenopausal disorders (including vasomotor symptoms associated with menopause, and vulvar and vaginal atrophy) and osteoporosis |
| Pat. No. 5210081 Alkali metal 8,9-dehydroestrone sulfate esters Claim Types: Composition | Feb 26, 2012 |
GASTROMARK (SUSPENSION) FERUMOXSIL
Drug Classes: DIAGNOSTICS, MISCELLANEOUS
NDA Applicant: ADV MAGNETICS NDA No.: 020410 Prod. No.: 001 RX (EQ 0.175MG IRON/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4827945 Biologically degradable superparamagnetic materials for use in clinical applications Claim Types: Diagnostic or surgical method; Method of use | May 9, 2006 | U-170: Method of obtaining an mr image using the composition/drug product as a contrast agent |
| Pat. No. 5069216 Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract Claim Types: Diagnostic or surgical method | May 9, 2006 | U-171: Methods of using the compound/drug product as an oral contrast agent in magnetic resonance imaging of the gastrointestinal tract |
| Pat. No. 5055288 Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides Claim Types: Composition | Oct 8, 2008 | |
| Pat. No. 5219554 Hydrated biodegradable superparamagnetic metal oxides Claim Types: Composition | Jun 15, 2010 |
FERIDEX I.V. (INJECTABLE) FERUMOXIDES
Drug Classes: DIAGNOSTICS, RADIOPAQUE & NONRADIOACTIVE
NDA Applicant: ADV MAGNETICS NDA No.: 020416 Prod. No.: 001 RX (EQ 11.2MG IRON/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4827945 Biologically degradable superparamagnetic materials for use in clinical applications Claim Types: Diagnostic or surgical method; Method of use | May 9, 2006 | U-144: Biologically degradable superparamagnetic materials for use in clinical applications |
| Pat. No. 4951675 Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging Claim Types: Diagnostic or surgical method | Aug 28, 2007 | U-143: Biodegradable superparamagnetic metal oxides as contrast agents for mr imaging |
| Pat. No. 5055288 Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides Claim Types: Composition | Oct 8, 2008 | |
| Pat. No. 5102652 Low molecular weight carbohydrates as additives to stabilize metal oxide compositions Claim Types: Formulation; Diagnostic or surgical method; Method of use; Process | Feb 6, 2009 | |
| Pat. No. 5219554 Hydrated biodegradable superparamagnetic metal oxides Claim Types: Composition | Jun 15, 2010 | |
| Pat. No. 5248492 Low molecular weight carbohydrates as additives to stabilize metal oxide compositions Claim Types: Formulation; Diagnostic or surgical method; Method of use; Method of improving a formulation | Sep 28, 2010 |
NEUTREXIN (INJECTABLE) TRIMETREXATE GLUCURONATE
Drug Classes: ANTINEOPLASTICS
NDA Applicant: MEDIMMUNE ONCOLOGY NDA No.: 020326 Prod. No.: 001 RX (EQ 25MG BASE/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4694007 Use of trimetrexate as antiparasitic agent Claim Types: Method of use | May 20, 2006 | U-91: Alternative therapy to trimethoprim-sulfamethoxazole for treatment of moderate-to-severe pneumocystis carinii pneumonia in immunocompromised and aids patients |
| Pat. No. 6017922 Thermally stable trimetrexates and processes for producing the same Claim Types: New polymorph, salt or hydrate; Composition | May 18, 2018 |
NASAREL (SPRAY, METERED) FLUNISOLIDE
Drug Classes: CORTICOSTEROIDS-INHALATION/NASAL
NDA Applicant: IVAX RES NDA No.: 020409 Prod. No.: 001 RX (0.029MG/SPRAY)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4782047 Aqueous steroid formulations for nasal administration Claim Types: Formulation; Method of use | May 22, 2006 | |
| Pat. No. 4983595 Aqueous steroid formulations for nasal administration Claim Types: Formulation | May 22, 2006 | |
| Pat. No. 4933168 Stable, crystalline flunisolide Claim Types: New polymorph, salt or hydrate; Formulation; Method of use | Jun 12, 2007 |
SPECTRACEF (TABLET) CEFDITOREN PIVOXIL
Drug Classes: CEPHALOSPORINS
NDA Applicant: PURDUE PHARMA LP NDA No.: 021222 Prod. No.: 001 RX (200MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4918068 Cephem compounds Claim Types: Compound; Composition | Jun 13, 2006 | |
| Pat. No. 4839350 DS* DP* [Extended 1036 days (2.8 years)] Cephalosporin compounds and the production thereof Claim Types: Compound; Composition | Apr 14, 2009 | |
| Pat. No. 5958915 Antibacterial composition for oral administration Claim Types: Formulation; Method of improving a formulation | Oct 14, 2016 | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: NCE - New chemical entity | AUG 29,2006 |
PROSCAR (TABLET) FINASTERIDE [GENERIC AB]
NDA Applicant: MERCK NDA No.: 020180 Prod. No.: 001 RX (5MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4760071 DS* DP* [Extended 328 days (0.9 years)] 17.beta.-N-monosubstituted carbamoyl-4-aza-5.alpha.-androst-1-en-3-ones which are active as testosterone 5.alpha.-reductase inhibitors Claim Types: Compound; Composition; Method of use | Jun 19, 2006 | U-262: Treating benign prostatic hypertrophy with finasteride |
| Pat. No. 6046183 DP* Method of synergistic treatment for benign prostatic hyperplasia Claim Types: Method of use; Composition | Mar 20, 2011 | U-577: Treatment of benign prostatic hyperplasia with finasteride in combination with doxazosin |
| Pat. No. 5886184 DS* Finasteride processes Claim Types: New polymorph, salt or hydrate; Product-by-process; Process | Nov 19, 2012 | |
| Pat. No. 5942519 Prevention of precipitated acute urinary retention Claim Types: Method of use | Oct 23, 2018 | U-280: Treating precipitated acute urinary retention with finasteride |
PROPECIA (TABLET) FINASTERIDE [GENERIC AB]
Drug Classes: ANDROGENS/ANABOLIC STEROIDS
NDA Applicant: MERCK NDA No.: 020788 Prod. No.: 001 RX (1MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4760071 [Extended 328 days (0.9 years)] 17.beta.-N-monosubstituted carbamoyl-4-aza-5.alpha.-androst-1-en-3-ones which are active as testosterone 5.alpha.-reductase inhibitors Claim Types: Compound; Composition; Method of use | Jun 19, 2006 | |
| Pat. No. 5886184 Finasteride processes Claim Types: New polymorph, salt or hydrate; Product-by-process; Process | Nov 19, 2012 | |
| Pat. No. 5547957 Method of treating androgenic alopecia with 5-.alpha. reductase inhibitors Claim Types: Method of use | Oct 15, 2013 | U-236: Treating male pattern baldness with 0.05 to 3.0 mg/day |
| Pat. No. 5571817 Methods of treating androgenic alopecia with finasteride [17.beta.-N-mono-substituted-carbamoyl-4-aza-5-.alpha.-androst-1-en-ones] Claim Types: Method of use | Nov 5, 2013 | U-259: Treatment of androgenic alopecia by oral administration of drug substance |
ZOCOR (TABLET) SIMVASTATIN [GENERIC AB]
Drug Classes: HYPERLIPIDEMIA
NDA Applicant: MERCK NDA No.: 019766 Prod. No.: 001 RX (5MG); 002 RX (10MG); 003 RX (20MG); 004 RX (40MG); 005 RX (80MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4444784 [Extended 1704 days (4.7 years)] Antihypercholesterolemic compounds Claim Types: Compound; Composition; Method of use | Jun 23, 2006 *PED | U-59: Method of treating hypercholesterolemia |
| Pat. No. RE36481 HMG-CoA reductase inhibitors Claim Types: Compound; Composition; Method of use | Jan 10, 2008 *PED | U-300: Indicated for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia |
| Pat. No. RE36520 HMG-CoA reductase inhibitors Claim Types: Compound; Composition; Method of use | Nov 26, 2009 *PED | U-300: Indicated for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: I - New Indication | Apr 18,2006 PED | I-350: Treatment of heterozygous familial hypercholesterolemia in adolescent boys and girls at least one year postmenarchal, ages 10 to 17 years, with a recommended dosing range of 10 to 40mg once daily |
| Exclusivity Code: I - New Indication | APR 16,2006 | I-390: Use in patients at high risk coronary events due to existing coronary heart disease, diabetes, peripheral vessel disease, stroke history, other CV disease to reduce risk total mortality by reducing coronary death, reduce nonfatal MI & stroke |
MIRAPEX (TABLET) PRAMIPEXOLE DIHYDROCHLORIDE
Drug Classes: CNS, MISCELLANEOUS; EXTRAPYRAMIDAL MOVEMENT DISORDERS
NDA Applicant: BOEHRINGER INGELHEIM NDA No.: 020667 Prod. No.: 001 RX (0.125MG); 002 RX (0.25MG); 003 RX (1MG); 005 RX (1.5MG); 006 RX (0.5MG) NDA No.: 020667 Prod. No.: 004 DISC (1.25MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4843086 Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals Claim Types: Method of use | Jun 27, 2006 | U-231: Use in Parkinson's disease |
| Pat. No. 4886812 [Extended 1564 days (4.3 years)] Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals Claim Types: Compound; Composition | Mar 25, 2011 |
ZOLOFT (TABLET) SERTRALINE HYDROCHLORIDE [GENERIC AB]
Drug Classes: ANTIDEPRESSANTS
NDA Applicant: PFIZER NDA No.: 019839 Prod. No.: 001 RX (EQ 50MG BASE); 002 RX (EQ 100MG BASE); 005 RX (EQ 25MG BASE) NDA No.: 019839 Prod. No.: 003 DISC (EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**); 004 DISC (EQ 200MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4536518 [Extended 1228 days* (3.4 years)] Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine Claim Types: Compound; Composition; Method of use | Jun 30, 2006 *PED | U-12: Method of treating [a] human suffering from depression |
| Pat. No. 5744501 Method for treating late luteal phase dysphoric disorder Claim Types: Method of use | Jan 6, 2009 | U-461: Method of treatment of late Luteal Phase Dysphoric Disorder (PMDD) using sertraline |
| Pat. No. 5789449 Treatment of symptoms associated with premenstrual disorders Claim Types: Method of use | Jan 6, 2009 | U-460: Method of treating psychiatric symptoms associated with premenstrual disorders using sertraline |
| Pat. No. 4962128 Method of treating anxiety-related disorders using sertraline Claim Types: Method of use | May 2, 2010 *PED | U-152: Method of treating anxiety related disorders including obsessive compulsive disorder |
| Pat. No. 5248699 Sertraline polymorph Claim Types: New polymorph, salt or hydrate; Composition; Method of use | Feb 13, 2013 *PED | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: I - New Indication | FEB 07,2006 | I-261: Treatment of social anxiety disorder |
ZOLOFT (CONCENTRATE) SERTRALINE HYDROCHLORIDE [GENERIC AB]
Drug Classes: ANTIDEPRESSANTS
NDA Applicant: PFIZER NDA No.: 020990 Prod. No.: 001 RX (EQ 20MG BASE/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4536518 [Extended 1228 days* (3.4 years)] Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine Claim Types: Compound; Composition; Method of use | Jun 30, 2006 *PED | U-286: Depression |
| Pat. No. 5744501 Method for treating late luteal phase dysphoric disorder Claim Types: Method of use | Jan 6, 2009 | U-461: Method of treatment of late Luteal Phase Dysphoric Disorder (PMDD) using sertraline |
| Pat. No. 5789449 Treatment of symptoms associated with premenstrual disorders Claim Types: Method of use | Jan 6, 2009 | U-460: Method of treating psychiatric symptoms associated with premenstrual disorders using sertraline |
| Pat. No. 5248699 Sertraline polymorph Claim Types: New polymorph, salt or hydrate; Composition; Method of use | Feb 13, 2013 *PED | |
| Pat. No. 6727283 DP* Sertraline oral concentrate Claim Types: Formulation; Process; Method of use | Apr 11, 2020 *PED | U-580: Treatment of disorders of the serotonergic system such as depression and anxiety-related disorders |
| Pat. No. 7067555 DP* Sertraline oral concentrate Claim Types: Process; Formulation | May 10, 2020 *PED | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: I - New Indication | FEB 07,2006 | I-261: Treatment of social anxiety disorder |
FERTINEX (INJECTABLE) UROFOLLITROPIN
Drug Classes: INFERTILITY
NDA Applicant: SERONO NDA No.: 019415 Prod. No.: 004 DISC (150 IU/AMP); 005 DISC (75 IU/AMP)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4845077 Method of inducing ovulation Claim Types: Method of use | Jul 4, 2006 | U-408: For inducing ovulation in conjunction with a gonadotropin releasing factor antagonist and recruiting oocytes for in-vitro fertilization |
| Pat. No. 5767067 Follicle stimulating hormone and pharmaceutical compositions containing same Claim Types: Composition | Jun 16, 2015 |
AROMASIN (TABLET) EXEMESTANE
Drug Classes: HORMONAL/BIOLOGICAL RESPONSE MODIFIERS
NDA Applicant: PHARMACIA AND UPJOHN NDA No.: 020753 Prod. No.: 001 RX (25MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4904650 DS* DP* Substituted androsta-1,4-diene-3,17-diones Claim Types: Compound; Composition; Method of use | Jul 7, 2006 | |
| Pat. No. 4808616 DS* DP* [Extended 1729 days (4.7 years)] 6-substituted androsta-1,4-diene-3,17-diones Claim Types: Compound; Composition; Method of use | Apr 1, 2011 | U-658: Treatment of advanced hormone-dependent breast cancer |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: I - New Indication | OCT 05,2008 | I-495: Adjuvant tx of postmenopausal women with estrogen-receptor positive early breast cancer who have received 2 to 3 yrs of tamoxifen and are switched to AROMASIN for completion of a total of 5 consecutive yrs of adjuvant hormonal therapy |
| Exclusivity Code ODE: Orphan Drug | OCT 21,2006 | Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. |
TECZEM (TABLET, EXTENDED RELEASE) DILTIAZEM MALATE; ENALAPRIL MALEATE
NDA Applicant: BIOVAIL NDA No.: 020507 Prod. No.: 001 RX (EQ 180MG HCL;5MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4968507 Controlled porosity osmotic pump Claim Types: Device | Jul 25, 2006 | |
| Pat. No. 4880631 Controlled porosity osmotic pump Claim Types: Device; Formulation | Sep 24, 2007 | |
| Pat. No. 4983598 Pharmaceutical composition containing diltiazem and angiotensin-converting enzyme inhibitor Claim Types: Composition; Method of use | Jan 8, 2008 |
XALATAN (SOLUTION/DROPS) LATANOPROST
Drug Classes: GLAUCOMA
NDA Applicant: PHARMACIA AND UPJOHN NDA No.: 020597 Prod. No.: 001 RX (0.005%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4599353 [Extended 1116 days (3.1 years)] Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma Claim Types: Method of use; Composition | Jul 28, 2006 | U-260: Reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are intolerant of other IOP lowering medications or insufficiently responsive to another iop lowering medication |
| Pat. No. 6429226 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension Claim Types: Composition; Method of use | Sep 6, 2009 | U-260: Reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are intolerant of other IOP lowering medications or insufficiently responsive to another iop lowering medication |
| Pat. No. 5296504 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension Claim Types: Composition; Method of use | Mar 22, 2011 | U-260: Reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are intolerant of other IOP lowering medications or insufficiently responsive to another iop lowering medication |
| Pat. No. 5422368 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension Claim Types: Composition; Method of use | Mar 22, 2011 | U-260: Reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are intolerant of other IOP lowering medications or insufficiently responsive to another iop lowering medication |
LOTREL (CAPSULE) AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE
Drug Classes: CALCIUM CHANNEL BLOCKERS; ACE INHIBITORS; ANTIHYPERTENSIVES
NDA Applicant: NOVARTIS NDA No.: 020364 Prod. No.: 002 RX (EQ 2.5MG BASE;10MG); 003 RX (EQ 5MG BASE;10MG); 004 RX (EQ 5MG BASE;20MG); 005 RX (EQ 10MG BASE;20MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4572909 [Extended 1252 days (3.4 years)] 2-(Secondary aminoalkoxymethyl) dihydropyridine derivatives as anti-ischaemic and antihypertensive agents Claim Types: Compound; Composition; Method of use Comments: Amlodipine and its salts, generally. | Jul 31, 2006 | |
| Pat. No. 4879303 Pharmaceutically acceptable salts Claim Types: Compound;Composition; Formulation | Mar 25, 2007 | |
| Pat. No. 6162802 Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor Claim Types: Method of use; Formulation | Dec 19, 2017 | U-367: Treatment of cardiovascular disorders |
DEMADEX (TABLET) TORSEMIDE [GENERIC AB]
Drug Classes: DIURETICS
NDA Applicant: ROCHE NDA No.: 020136 Prod. No.: 001 RX (5MG); 002 RX (10MG); 003 RX (20MG); 004 RX (100MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. RE34672 Pharmaceutical composition containing a stable modification of torasemide Claim Types: New polymorph, salt or hydrate; Method of use | Aug 11, 2006 |
DEMADEX (INJECTABLE) TORSEMIDE
Drug Classes: DIURETICS
NDA Applicant: ROCHE NDA No.: 020137 Prod. No.: 002 RX (10MG/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. RE34672 Pharmaceutical composition containing a stable modification of torasemide Claim Types: New polymorph, salt or hydrate; Method of use | Aug 11, 2006 | |
| Pat. No. 4861786 Composition for a stable vein compatible injectable solution of torasemide process for the preparation and method of use Claim Types: Formulation; Kit; Method of use | Jul 8, 2007 |
ACEON (TABLET) PERINDOPRIL ERBUMINE
Drug Classes: ACE INHIBITORS
NDA Applicant: SOLVAY PHARMS NDA No.: 020184 Prod. No.: 001 RX (2MG); 002 RX (4MG); 003 RX (8MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4508729 [Extended 1601 days (4.4 years)] Substituted iminodiacids, their preparation and pharmaceutical compositions containing them Claim Types: Compound; Composition; Method of use | Aug 21, 2006 | |
| Pat. No. 5162362 DS* DP* Octahydroindole-2-carboxylic acids Claim Types: Compound; Composition; Method of use | Nov 10, 2009 | U-531: Treatment of patients with essential hypertension. May be used alone or given with other classes of antihypertensives, especially thiazide derivatives |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: I - New Indication | AUG 23,2008 | I-468: Use in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infection |
PRANDIN (TABLET) REPAGLINIDE
Drug Classes: BLOOD GLUCOSE REGULATORS
NDA Applicant: NOVO NORDISK INC NDA No.: 020741 Prod. No.: 001 RX (0.5MG); 002 RX (1MG); 003 RX (2MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5312924 Phenylacetic acid benzylamides Claim Types: Compound; Method of use | Sep 5, 2006 | U-214: Use as a blood glucose-lowering agent |
| Pat. No. 6143769 Phenylacetic acid benzylamides Claim Types: Composition | Sep 5, 2006 | |
| Pat. No. RE37035 [Extended 921 days (2.5 years)] Phenylacetic acid benzylamides Claim Types: Compound; Composition | Mar 14, 2009 | |
| Pat. No. 6677358 DS* DP* NIDDM regimen Claim Types: Composition; Method of use; Kit | Jun 12, 2018 | U-546: Use of repaglinide in combination with metformin to lower blood glucose |
FASLODEX (INJECTABLE) FULVESTRANT
Drug Classes: ESTROGENS/PROGESTINS
NDA Applicant: ASTRAZENECA NDA No.: 021344 Prod. No.: 001 RX (50MG/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4659516 [Extension length not available] Steroid derivatives Claim Types: Compound; Method of use | Oct 1, 2006 | |
| Pat. No. 6774122 Formulation Claim Types: Method of use | Jan 9, 2021 | U-596: Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: NCE - New chemical entity | APR 25,2007 |
TILADE (AEROSOL, METERED) NEDOCROMIL SODIUM
Drug Classes: ANTIASTHMATICS/BRONCODILATORS
NDA Applicant: KING PHARMS NDA No.: 019660 Prod. No.: 001 RX (1.75MG/INH)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4474787 [Extended 5 years] 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof Claim Types: Compound; Composition; Method of use | Oct 2, 2006 |
ALOCRIL (SOLUTION/DROPS) NEDOCROMIL SODIUM
Drug Classes: OPHTHALMICS-DECONGESTANTS/ANTIALLERGY AGENTS
NDA Applicant: ALLERGAN NDA No.: 021009 Prod. No.: 001 RX (2%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4474787 [Extended 5 years] 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof Claim Types: Compound; Composition; Method of use | Oct 2, 2006 | U-304: A method of treatment of a condition involving an antibody antigen reaction |
| Pat. No. RE38628 Pharmaceutical compositions Claim Types: Method of use | Aug 22, 2012 | U-304: A method of treatment of a condition involving an antibody antigen reaction |
PATANOL (SOLUTION/DROPS) OLOPATADINE HYDROCHLORIDE
Drug Classes: OPHTHALMICS-DECONGESTANTS/ANTIALLERGY AGENTS
NDA Applicant: ALCON NDA No.: 020688 Prod. No.: 001 RX (EQ 0.1% BASE)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4871865 Tricyclic aromatic compounds Claim Types: Compound | Oct 3, 2006 | |
| Pat. No. 4923892 Tricyclic aromatic compounds Claim Types: Composition; Method of use | May 8, 2007 | U-174: Use as an antihistamine agent |
| Pat. No. 5116863 [Extended 571 days* (1.6 years)] Dibenz[b,e]oxepin derivative and pharmaceutical compositions thereof Claim Types: Compound; Composition | Dec 18, 2010 | |
| Pat. No. 5641805 Topical ophthalmic formulations for treating allergic eye diseases Claim Types: Method of use | Jun 6, 2015 | U-184: Treating allergic eye diseases in humans |
AMBIEN (TABLET) ZOLPIDEM TARTRATE
Drug Classes: SEDATIVES/HYPNOTICS
NDA Applicant: SANOFI AVENTIS US NDA No.: 019908 Prod. No.: 001 RX (5MG); 002 RX (10MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4382938 [Extended 5 years] Imidazo[1,2-a] pyridine derivatives and their application as pharmaceuticals Claim Types: Compound; Method of use | Oct 21, 2006 | U-74: Method of providing hypnotic effect |
AMBIEN CR (TABLET, EXTENDED RELEASE) ZOLPIDEM TARTRATE
NDA Applicant: SANOFI AVENTIS US NDA No.: 021774 Prod. No.: 001 RX (12.5MG); 002 RX (6.25MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4382938 DS* [Extended 5 years] Imidazo[1,2-a] pyridine derivatives and their application as pharmaceuticals Claim Types: Compound; Method of use | Oct 21, 2006 | U-682: Non-benzodiazepine hypnotic agent indicated for treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance |
| Pat. No. 6514531 DP* Controlled-release dosage forms comprising zolpidem or a salt thereof Claim Types: Formulation | Dec 1, 2019 | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: NDF - New dosage form | SEP 02,2008 |
CARDENE (INJECTABLE) NICARDIPINE HYDROCHLORIDE
Drug Classes: ANTIHYPERTENSIVES
NDA Applicant: PDL BIOPHARMA INC NDA No.: 019734 Prod. No.: 001 RX (2.5MG/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4880823 Injection of nicardinpine hydrochloride and process for the production thereof Claim Types: Formulation | Nov 14, 2006 | |
| Pat. No. 5164405 Nicardipine pharmaceutical composition for parenteral administration Claim Types: Composition; Process | Nov 17, 2009 |
PROHANCE (INJECTABLE) GADOTERIDOL
Drug Classes: DIAGNOSTICS, RADIOPAQUE & NONRADIOACTIVE
NDA Applicant: BRACCO NDA No.: 020131 Prod. No.: 001 RX (279.3MG/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4885363 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs Claim Types: Compound; Composition | Dec 5, 2006 | |
| Pat. No. 5474756 Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl- 1,4,7,10-tetraazacyclododecane and analogs Claim Types: Diagnostic or surgical method | Dec 12, 2012 | U-480: Contrast agent for MRI |
| Pat. No. 6143274 Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl- 1,4,7,10-tetraazacyclododecane and analogs Claim Types: Diagnostic or surgical method; Method of use | Dec 12, 2012 | U-480: Contrast agent for MRI |
| Pat. No. 5846519 Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl- 1,4,7,10-tetraazacyclododecane and analogs Claim Types: Formulation | Dec 8, 2015 |
PROHANCE MULTIPACK (INJECTABLE) GADOTERIDOL
Drug Classes: DIAGNOSTICS, RADIOPAQUE & NONRADIOACTIVE
NDA Applicant: BRACCO NDA No.: 021489 Prod. No.: 001 RX (279.3MG/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4885363 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs Claim Types: Compound; Composition | Dec 5, 2006 | |
| Pat. No. 5474756 Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl- 1,4,7,10-tetraazacyclododecane and analogs Claim Types: Diagnostic or surgical method | Dec 12, 2012 | U-536: Contrast agent for magnetic resonace imaging |
| Pat. No. 6143274 Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl- 1,4,7,10-tetraazacyclododecane and analogs Claim Types: Diagnostic or surgical method; Method of use | Dec 12, 2012 | U-536: Contrast agent for magnetic resonace imaging |
| Pat. No. 5846519 Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl- 1,4,7,10-tetraazacyclododecane and analogs Claim Types: Formulation | Dec 8, 2015 |
PAXIL CR (TABLET, EXTENDED RELEASE) PAROXETINE HYDROCHLORIDE
Drug Classes: ANTIDEPRESSANTS
NDA Applicant: GLAXOSMITHKLINE NDA No.: 020936 Prod. No.: 001 RX (EQ 12.5MG BASE); 002 RX (EQ 25MG BASE); 003 RX (EQ 37.5MG BASE)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4839177 System for the controlled-rate release of active substances Claim Types: Device; Process | Dec 13, 2006 *PED | |
| Pat. No. 4721723 [Extended 67 days* (0.2 years)] Anti-depressant crystalline paroxetine hydrochloride hemihydrate Claim Types: New polymorph, salt or hydrate; Composition; Process; Method of use | Jun 29, 2007 *PED | |
| Pat. No. 5789449 Treatment of symptoms associated with premenstrual disorders Claim Types: Method of use | Jul 6, 2009 *PED | U-286: Depression |
| Pat. No. 5422123 Tablets with controlled-rate release of active substances Claim Types: Formulation; Process | Dec 6, 2012 *PED | |
| Pat. No. 5872132 Form of paroxetine hydrochloride anhydrate Claim Types: New polymorph, salt or hydrate; Composition | Nov 19, 2015 *PED | |
| Pat. No. 5900423 Form of paroxetine hydrochloride anhydrate Claim Types: New polymorph, salt or hydrate | Nov 19, 2015 *PED | |
| Pat. No. 6133289 Paroxetine hydrochloride form A or C Claim Types: Method of using new polymorph, salt or hydrate | Nov 19, 2015 *PED | U-286: Depression |
| Pat. No. 6548084 Controlled release compositions Claim Types: Method of improving a treatment; Formulation; Process | Jan 19, 2017 *PED | |
| Pat. No. 6121291 Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder Claim Types: Method of use | Sep 17, 2017 *PED | U-286: Depression |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: D - New Dosing Schedule | JAN 27,2007 | D-91: Alternate intermittent dosing regimen |
| Exclusivity Code: I - New Indication | AUG 28,2006 | I-405: Treatment of Premenstrual Dysphoric Disorder (PMDD) using an intermittent dosing regimen |
LAMISIL (CREAM) TERBINAFINE HYDROCHLORIDE
Drug Classes: DERMATOLOGICS
NDA Applicant: NOVARTIS NDA No.: 020192 Prod. No.: 001 DISC (1%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4755534 [Extended 543 days (1.5 years)] Propenylamines, pharmaceutical compositions containing them and their use as pharmaceuticals Claim Types: Compound; Composition; Method of use | Dec 30, 2006 | U-73: Method of treating diseases or infections caused by mycetes |
LAMISIL (TABLET) TERBINAFINE HYDROCHLORIDE
Drug Classes: ANTIFUNGALS
NDA Applicant: NOVARTIS NDA No.: 020539 Prod. No.: 001 RX (EQ 250MG BASE)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4755534 [Extended 543 days (1.5 years)] Propenylamines, pharmaceutical compositions containing them and their use as pharmaceuticals Claim Types: Compound; Composition; Method of use | Dec 30, 2006 | U-73: Method of treating diseases or infections caused by mycetes |
LAMISIL (SOLUTION) TERBINAFINE HYDROCHLORIDE
Drug Classes: ANTIFUNGALS; TOPICAL ANTI-INFECTIVES
NDA Applicant: NOVARTIS NDA No.: 020749 Prod. No.: 001 RX (1%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4755534 [Extended 543 days (1.5 years)] Propenylamines, pharmaceutical compositions containing them and their use as pharmaceuticals Claim Types: Compound; Composition; Method of use | Dec 30, 2006 | |
| Pat. No. 6121314 Pharmaceutical composition Claim Types: Formulation; Method of use; Process | May 18, 2012 | U-502: Pityriasis Versicolor |
LAMISIL (GEL) TERBINAFINE
NDA Applicant: NOVARTIS NDA No.: 020846 Prod. No.: 001 RX (1%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4755534 [Extended 543 days (1.5 years)] Propenylamines, pharmaceutical compositions containing them and their use as pharmaceuticals Claim Types: Compound; Composition; Method of use | Dec 30, 2006 | U-445: Use as an antimycotic agent |
| Pat. No. 5856355 DP* Pharmaceutical composition Claim Types: Formulation; Process; Method of use | May 18, 2012 | U-502: Pityriasis Versicolor |
| Pat. No. 5856355 DP* Pharmaceutical composition Claim Types: Formulation; Process; Method of use | May 18, 2012 | U-504: Tinea Pedis, Tinea Cruris, Tinea Corporis |
| Pat. No. 5856355 DP* Pharmaceutical composition Claim Types: Formulation; Process; Method of use | May 18, 2012 | U-540: Treatment of fungal infections |
| Pat. No. 6005001 DP* Pharmaceutical composition Claim Types: Composition; Process; Method of use | May 18, 2012 | U-502: Pityriasis Versicolor |
| Pat. No. 6005001 DP* Pharmaceutical composition Claim Types: Composition; Process; Method of use | May 18, 2012 | U-504: Tinea Pedis, Tinea Cruris, Tinea Corporis |
| Pat. No. 6005001 DP* Pharmaceutical composition Claim Types: Composition; Process; Method of use | May 18, 2012 | U-540: Treatment of fungal infections |
| Pat. No. 6121314 DP* Pharmaceutical composition Claim Types: Formulation; Method of use; Process | May 18, 2012 | U-502: Pityriasis Versicolor |
| Pat. No. 6121314 DP* Pharmaceutical composition Claim Types: Formulation; Method of use; Process | May 18, 2012 | U-504: Tinea Pedis, Tinea Cruris, Tinea Corporis |
| Pat. No. 6121314 DP* Pharmaceutical composition Claim Types: Formulation; Method of use; Process | May 18, 2012 | U-540: Treatment of fungal infections |
| Pat. No. 5681849 DP* Pharmaceutical composition for topical applications Claim Types: Formulation; Method of use | Oct 28, 2014 |
LAMISIL (CREAM) TERBINAFINE HYDROCHLORIDE
NDA Applicant: NOVARTIS NDA No.: 020980 Prod. No.: 001 OTC (1%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4755534 [Extended 543 days (1.5 years)] Propenylamines, pharmaceutical compositions containing them and their use as pharmaceuticals Claim Types: Compound; Composition; Method of use | Dec 30, 2006 | U-73: Method of treating diseases or infections caused by mycetes |
LAMISIL AT (SOLUTION; SPRAY) TERBINAFINE HYDROCHLORIDE
NDA Applicant: NOVARTIS NDA No.: 021124 Prod. No.: 001 OTC (1%); 002 OTC (1%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4755534 [Extended 543 days (1.5 years)] Propenylamines, pharmaceutical compositions containing them and their use as pharmaceuticals Claim Types: Compound; Composition; Method of use | Dec 30, 2006 | U-73: Method of treating diseases or infections caused by mycetes |
| Pat. No. 6121314 Pharmaceutical composition Claim Types: Formulation; Method of use; Process | May 18, 2012 | U-504: Tinea Pedis, Tinea Cruris, Tinea Corporis |
| Pat. No. 5681849 Pharmaceutical composition for topical applications Claim Types: Formulation; Method of use | Oct 28, 2014 |